Adapting IPF Clinical Trials in a Changing Treatment Landscape: Incorporating New Standards of Care Without Compromising Study Integrity
- Exploring how Cumberland amended its IPF trial to allow newly approved therapies as background treatment, ensuring patients can access the latest options while maintaining scientific rigor in evaluating investigational therapies
- Understanding how patient demand for newly approved drugs can influence recruitment, retention, and protocol design, and how proactive site engagement and investigator feedback informed trial modifications
- Lessons from patient experiences with antifibrotics and newer therapies, highlighting how tolerability challenges can influence treatment decisions, trial participation, and the interpretation of clinical outcomes